Shalby Ltd (SHALBY) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Shalby reported consolidated revenue of INR 270 crores, an 8.4% increase YoY, driven by the full-year consolidation of Sanar Hospitals and growth in the implant business.
- Consolidated EBITDA decreased by 40% YoY to INR 26.2 crores, primarily due to losses in Sanar and investments in the implant business.
- Standalone hospital revenue grew by 1.7% YoY, reaching INR 214 crores.
- Shalby MedTech (implant business) achieved significant revenue growth of 138% YoY, reaching INR 29 crores in Q4.
- The company maintained a strong balance sheet with a low gearing ratio of 0.2.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.